Liguo Li

Liguo Li

Auto-generated profile, based on publicly available information

Liguo Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021
Verified
Book Chapter
Open access
PDF file
YHYanan Hou
Yanan Hou
LLLiguo Li
Liguo Li
JKJoseph H Koo
Joseph H Koo
Thick-section composites (TSC) are extensively demanded in many fields, such as aerospace, wind energy, and oil and gas industries. However, the manufacturing process of thick-section thermoset composites (TSSC) encounters significant complexities, such as variations of nonuniform resin flow, exothermal reaction and curing, and dimensional stability through the thickness direction. These process-related nonuniformities are expected to result in through-thickness gradients of mechanical properties and curing-induced deformations, leading to undesirable residual stresses and damage. This chapter introduces the application of TSC and issues related to its manufacturing processes. Methods of TSC are examined and analyzed. Fundamental characteristics of curing kinetics, thermal transfer, and residual stress in TSC will be explained. Research of detailed experiments will be referred for readers for further studies.

23 January 2019
Verified
Book Chapter
Open access
PDF file
JYJiazhao Yang
Jiazhao Yang
SFShiyuan Fang
Shiyuan Fang
LXLei Xu
Lei Xu
LLLi Li
Li Li
KXKai Xie
Kai Xie
LKLixin Kan
Lixin Kan
Mesenchymal stromal cells (MSCs) have the capacity for self-renewal and multi-lineage differentiation, have many advantages over other cells, and are thought to be one of the most promising cell sources for cell-based treatments. In fact, MSCs have already been widely applied in clinics as a treatment for numerous disorders, including orthopedic diseases, such as bone fracture, articular cartilage injury, osteoarthritis (OA), femoral head necrosis, degenerative disc, meniscus injury, osteogenesis imperfecta (OI), and other systemic bone diseases. With the progressions in R&D, the safety and efficacy of MSC-based treatments in orthopedic diseases have been largely recognized, but many challenges still exist. In this chapter, we intend to briefly update the recent progressions and discuss the potential issues in the target areas. Hopefully, our discussion would be helpful not only for the clinicians and the researchers in the specific disciplines but also for the general audiences.